Search Results
Baxter Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock.
Bleeding: You Don't Really Know It Until You Can Name It
Dr. Natalia Peres Martinez, MD, MSc, PhD, MBA, is a general surgeon and seasoned Medical Affairs Executive with a distinguished career in the medical device and pharmaceutical industries. With expertise spanning general surgery, cancer molecular biology, and Patient Blood Management (PBM), she brings a unique blend of clinical insight and strategic leadership. As one of the early collaborators with the Society for the Advancement of Blood Management (SABM), Dr.
The Baxter Foundation Announces $2.6M Grant to Advance STEM Education in Chicagoland Through Partnership with Northwestern University
The Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the continuation of a partnership with Northwestern University’s School of Education and Social Policy (SESP) to provide science, technology, engineering and math (STEM) programs for students and teachers throughout the Chicagoland area.
Advancing Patient Safety: Baxter's Leadership in Patient Blood Management and Strategic Collaborations
In today’s surgical landscape, where precision and outcomes are paramount, Baxter’s Advanced Surgery Division stands at the forefront of advancing Patient Blood Management (PBM), a patient-centered, evidence-based approach to optimizing blood use and minimizing transfusions.
Baxter Reports Third-Quarter 2025 Results
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025.
Passion for innovation continues to shine brightly for Gianni Di Stefani
Gianni Di Stefani started his career at a small start-up company. His involvement in the development of stents (used to treat narrowed arteries) ignited a passion for research and development (R&D). Having spent nearly three decades working within the R&D team at Baxter, that same passion for his work continues to shine!
Baxter to Host Third-Quarter 2025 Financial Results Conference Call
Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its third-quarter 2025 financial results on Thursday, October 30, 2025 at 7:30 a.m. Central Time.
Leading with Heart: Donielle Johnson Helping to Shape Patient-Focused Innovation
Donielle Johnson, Global Head of Regulatory Affairs for Baxter's Advanced Surgery business, represents the company on the governance team of The National Evaluation System for Health Technology (NEST). With over 20 years of experience in MedTech and a background in chemistry, Donielle has built her career around navigating the complex regulatory landscape of medical devices and combination products. But her work is driven by more than expertise, it’s rooted in a deep personal purpose.
Moving Care Forward in the Emergency Department
A clinician’s perspective on setting a new standard for support in the toughest environments
Remembering Melissa: A Story of Love, Courage, and Community
At Baxter, our people shape our Mission to Save and Sustain Lives every day. In this story we remember Melissa Guinn, a mother, wife, daughter, former colleague and friend, whose life and legacy continue to inspire us.